|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1031.30
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 15.11 | 8.38 | 14.42 | 13.22 | 14.06 | CEPS(Rs) | 19.94 | 13.05 | 18.82 | 17.41 | 17.56 | DPS(Rs) | 6.00 | 2.50 | 3.50 | 3.50 | 3.50 | Book NAV/Share(Rs) | 134.78 | 129.30 | 124.46 | 109.96 | 83.68 | Tax Rate(%) | 24.75 | 26.29 | 12.57 | 13.10 | 17.31 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 24.98 | 22.57 | 29.56 | 22.37 | 26.91 | EBIT Margin(%) | 26.49 | 16.55 | 22.54 | 28.23 | 30.36 | Pre Tax Margin(%) | 23.30 | 14.83 | 21.63 | 24.54 | 28.84 | PAT Margin (%) | 17.53 | 10.93 | 18.91 | 21.33 | 23.85 | Cash Profit Margin (%) | 23.13 | 17.03 | 24.69 | 28.08 | 29.78 | Performance Ratios | | | | | | ROA(%) | 7.11 | 4.29 | 7.72 | 8.15 | 10.17 | ROE(%) | 11.38 | 6.60 | 12.30 | 13.65 | 17.65 | ROCE(%) | 13.45 | 7.98 | 11.13 | 13.22 | 16.10 | Asset Turnover(x) | 0.41 | 0.39 | 0.41 | 0.38 | 0.43 | Sales/Fixed Asset(x) | 1.11 | 1.07 | 1.15 | 1.00 | 1.13 | Working Capital/Sales(x) | 2.00 | 2.79 | 6.45 | 4.72 | 4.15 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.90 | 0.94 | 0.87 | 1.00 | 0.88 | Receivable days | 121.00 | 97.23 | 101.96 | 131.36 | 101.78 | Inventory Days | 77.60 | 86.18 | 74.23 | 82.44 | 84.43 | Payable days | 148.14 | 162.08 | 182.09 | 172.30 | 177.24 | Valuation Parameters | | | | | | PER(x) | 32.53 | 41.62 | 30.58 | 20.21 | 24.65 | PCE(x) | 24.65 | 26.71 | 23.42 | 15.34 | 19.74 | Price/Book(x) | 3.65 | 2.70 | 3.54 | 2.43 | 4.14 | Yield(%) | 1.22 | 0.72 | 0.79 | 1.31 | 1.01 | EV/Net Sales(x) | 6.22 | 4.86 | 6.29 | 4.83 | 6.45 | EV/Core EBITDA(x) | 18.09 | 18.15 | 20.39 | 13.49 | 17.78 | EV/EBIT(x) | 23.51 | 29.31 | 27.80 | 17.11 | 21.26 | EV/CE(x) | 2.35 | 1.91 | 2.43 | 1.69 | 2.58 | M Cap / Sales | 5.70 | 4.56 | 5.80 | 4.31 | 5.88 | Growth Ratio | | | | | | Net Sales Growth(%) | 11.42 | 0.73 | 22.57 | 5.13 | 3.92 | Core EBITDA Growth(%) | 43.21 | -12.56 | 5.52 | 3.71 | 18.17 | EBIT Growth(%) | 77.89 | -26.18 | -1.80 | -2.26 | 17.42 | PAT Growth(%) | 78.25 | -41.88 | 9.06 | -5.99 | 31.99 | EPS Growth(%) | 80.36 | -41.88 | 9.06 | -5.99 | 31.99 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.35 | 0.20 | 0.31 | 0.33 | 0.42 | Current Ratio(x) | 2.08 | 1.57 | 1.23 | 1.34 | 1.47 | Quick Ratio(x) | 1.64 | 1.18 | 0.89 | 0.99 | 0.99 | Interest Cover(x) | 8.30 | 9.63 | 24.82 | 7.66 | 19.99 | Total Debt/Mcap(x) | 0.10 | 0.07 | 0.09 | 0.14 | 0.10 |
|
|
|
|
|
|